Advancis changes name--again

Prodded by attorneys from Sanofi-Aventis, Advancis has changed its name to MiddleBrook, which earns a few scoffs from the Health Blog of The Wall Street Journal. "Sounds more like a furniture store than a drug company," noted the writer. To Sanofi, though, Advancis sounded too much like Aventis and a judge agreed. MiddleBrook is now for sale, though, and the company notes that it's likely to take on the new name of anyone who acquires it. For the Advancis people, that would be their fifth, an final, name change.

- read the report from the Journal's blog (sub. req.)

Related Articles:
FDA rejects Advancis' NDA on strep therapy. Report
FDA says Advancis ready to file. Report
Advancis readies Phase III Pulsys trial. Report
Advancis drug flunks trial. Report

Suggested Articles

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.

The FDA’s advisory committee chair has stepped down from reviewing the upcoming pandemic vaccines given her role in Moderna’s COVID-19 test.

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"